P2.01-33 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-Pd-(L)1 Containing Therapy (HUDSON)
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1087
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV